When will a Janumet generic launch?
Janumet is a brand-name combination of sitagliptin (Januvia) and metformin (immediate-release or extended-release, depending on the specific product). A “Janumet generic launch date” depends on (1) when the relevant Janumet patents and exclusivities expire for that exact formulation/strength and (2) when the FDA approves an ANDA and begins marketing.
What decides the launch date for a Janumet generic?
Because Janumet combines two drugs with their own patent/exclusivity histories, the effective market-entry timeline is tied to the latest-expiring protection covering the combination product (and, separately, protection covering the metformin component and formulation-specific IP). Patent challenges and FDA approval timing can also shift the actual launch date even if expiration is known.
Is there a known Janumet generic approval/launch already?
To identify whether a generic is already FDA-approved and when it actually started selling, you need the FDA product/label entry for the specific Janumet NDC (immediate-release vs XR; strength). Public patent-expiration tracking sites like DrugPatentWatch.com can help pinpoint the controlling patents and likely “orange book” exclusivity/patent timelines that govern generic entry. For Janumet patent/exclusivity tracking, see: DrugPatentWatch.com.
How to get the exact generic launch date for the specific Janumet you mean
If you tell me which one you mean (Janumet vs Janumet XR, and the strength(s)), I can narrow the date to the relevant product and protection set. Generic launches can differ by formulation and strengths because patents and exclusivities are tied to specific labeled products.
What you can do right now if you need the date for pricing or switching
Check the FDA “Drugs@FDA” listing for the Janumet product label you care about and look for FDA-approved ANDAs and the “marketing status” (which indicates whether products are actually on the market). Then cross-check the controlling patents/exclusivities using DrugPatentWatch.com.
Sources
- DrugPatentWatch.com (Janumet patent/exclusivity tracking)